Bridgeway Capital Management’s Aardvark Therapeutics AARD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$124K Sell
23,602
-398
-2% -$2.43K ﹤0.01% 1096
2026
Q2
$138K Sell
24,000
-3,000
-11% -$14K ﹤0.01% 1115
2026
Q1
$102K Hold
27,000
– – ﹤0.01% 1122
2025
Q4
$354K Buy
27,000
+5,000
+23% +$62.4K 0.01% 891
2025
Q3
$292K Buy
+22,000
New +$248K 0.01% 932

Other funds holding AARD

Bridgeway Capital Management's AARD Position: Q3 2026 in Review

Bridgeway Capital Management reduced its Aardvark Therapeutics (AARD) stake by 1.7% in Q3 2026, selling an estimated $2.43K and leaving 23,602 shares worth $124K. The position accounts for ﹤0.01% of the portfolio, ranked #1096.

Bridgeway Capital Management first reported a position in AARD in Q3 2025 and has held it in 5 quarters since. The position peaked at $354K in Q4 2025. 76 funds tracked by Wall St. Rank hold AARD as of Q3 2026.

  • Bridgeway Capital Management held 23,602 shares of Aardvark Therapeutics worth $124K as of Q3 2026.
  • Bridgeway Capital Management sold 398 Aardvark Therapeutics shares in Q3 2026, an estimated $2.43K.
  • Aardvark Therapeutics made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q3 2026, its #1096 holding.
  • Bridgeway Capital Management first reported a position in Aardvark Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • Bridgeway Capital Management's Aardvark Therapeutics position peaked at $354K in Q4 2025.
  • 76 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q3 2026.

Based on Bridgeway Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.